11beta-hydroxysteroid dehydrogenase type 1 inhibitor AZD4017

A selective, orally bioavailable inhibitor of the enzyme 11beta-hydroxysteroid dehydrogenase type 1 (11b-HSD1; 11bHSD1; HSD11B1), with potential protective activity. Upon administration, AZD4017 selectively binds to and inhibits the activity of 11b-HSD1. This prevents the conversion of cortisone to the active hormone cortisol that activates glucocorticoid receptors. By blocking cortisol production in metabolic tissues, AZD4017 may inhibit the adverse metabolic effects, such as glucose intolerance, hyperinsulinemia, systolic hypertension, increased adiposity, myoatrophy and dermal atrophy, caused by exogenous administration of glucocorticoids in these tissues. 11bHSD1 is highly expressed in metabolic tissues, such as liver, skeletal muscle, and adipose tissue. It plays a crucial role in regenerating active glucocorticoid from circulating glucocorticoids and regulates the production of cortisol to activate the glucocorticoid receptors. AZD4017 does not inhibit the anti-inflammatory activity of the administered glucocorticoids.

Learn more about 11beta-hydroxysteroid dehydrogenase type 1 inhibitor AZD4017

• Dailymed label info
• Scientific articles
• Drug portal 11beta-hydroxysteroid dehydrogenase type 1 inhibitor AZD4017
• toxicity info on 11beta-hydroxysteroid dehydrogenase type 1 inhibitor AZD4017
• FDA 11beta-hydroxysteroid dehydrogenase type 1 inhibitor AZD4017

Latest research - 11beta-hydroxysteroid dehydrogenase type 1 inhibitor AZD4017

• Most recent articles
• Most cited
• Ongoing trials

External links

• Wikipedia's article on 11beta-hydroxysteroid dehydrogenase type 1 inhibitor AZD4017

This WikiMD article 11beta-hydroxysteroid dehydrogenase type 1 inhibitor AZD4017 is a stub. If you are familiar with the topic 11beta-hydroxysteroid dehydrogenase type 1 inhibitor AZD4017, you can help us. Paid editors welcome!